Navigation Links
Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Date:10/15/2007

AMSTERDAM, October 15 /PRNewswire/ -- Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced today that it has acquired the rights to the discovery of a major mechanism of resistance to the frequently-used breast cancer drug Herceptin(R), which is published in the October 15 issue of the journal "Cancer Cell".

The antibody drug Herceptin(R) targets the HER2 protein, which is hyper-active in about one in four breast cancers and the HER2 protein contributes to aggressive cancer behavior. Striking initial responses are observed in combination with chemotherapy in more than half of treated patients. However, the majority of responding patients eventually develop resistance to Herceptin-based therapies. The laboratory of Agendia's Chief Scientific Officer, Prof. Rene Bernards, today published a rapid method to identify biomarkers associated with non-responsiveness to cancer drugs in cell culture and used the technology to identify a mechanism of resistance to Herceptin-based cancer therapy. His work also demonstrated that these biomarkers indeed have predictive value in patients treated with this drug, thus validating the approach.

"The availability of biomarkers that predict responses to cancer therapy is instrumental to the rational use of cancer drugs in the clinic. Elucidating the molecular mechanism of drug resistance can be critical to identify patients that fail to respond to therapy and may help design more efficient treatment protocols", says Rene Bernards. "Although more work is needed to further validate our findings, the method is generally applicable to find mechanisms of drug resistance and should expedite the development of biomarkers that are associated with therapy non-responsiveness".

The technology used relies on the simultaneous inactivation of thousands of genes through a process known as RNA interference in cells that are sensitive to a specific cancer drug. If the inactivation of a specif
'/>"/>

SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Fiserv acquires crime management software firm
2. GenTel acquires GlaxoSmithKline chip platform
3. Tushaus Computer acquires managed service business
4. RedPrairie acquires Denver software company
5. Eagle Technology acquires some synergy
6. Brady Corp. acquires Korean counterpart
7. Canadian firm acquires Silicon Logic
8. Imago acquires synergistic British firm
9. Fiserv acquires insurance, training product lines
10. Amazon acquires Madison-based Shopbop
11. Metavante acquires health-care payments firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... ) has announced the addition of Jain ... Markets and Companies" to their offering. ... several technologies besides fluorescence in situ hybridization ... FISH. Molecular cytogenetics includes application of nanobiotechnology, ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International ... recognising ,outstanding, science that uses its patented antibody. ... novel prostate cancer diagnostic test known as MiCheck® next ... out the peer-reviewed Australian Museum Eureka Science Prize for ... This prize is awarded for ground breaking research that ...
(Date:9/2/2015)... Israel , September 2, 2015 ... the intent of the National Institute of Allergy and Infectious ... (NIH) within the Department of Health and Human Services (HHS), ... in the United States in the ... universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's new ... waste to energy process and continue to contribute to the sustainability of our ... Waste to Energy process has been operating at their Mexico facility, Recicladora Temarry, ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... five abstracts have been,selected for presentation at the ... from April 12-16, 2008 in San Diego, California.,The ... findings,about its CD44, TROP-2, CD59, and CD9 antibody ...
... Time to Brazil ... and ... of the Sanofi-aventis Group, announced today that six,million doses of Stamaril(TM)(1) ... the yellow fever epidemic in Latin,America., Brazil received four million ...
... - $2 M to ProMetic over the next 12 months - $30 M ... ... in-licensed ProMetic,s yield improving technology, - Incorporation of ProMetic,s prion reduction technology ... manufacturing process, ...
Cached Biology Technology:ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting 2ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting 3Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America 2Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 2ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 4
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Arabia Biomedical Sensors market is estimated at $0.23 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015 ... on consumers that are active and healthy. However, ... in the hospital environment to help improve diagnostic ... a video from the Wearable Technologies Conference ... discussed new applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... A team of scientists from The Scripps Research ... the deadliest antibiotic-resistant bacteria. The compound could one day ... highly resistant bacterial infections. The results were published ... of the American Chemical Society . "[These results] ...
... AURORA, Colo. (Aug. 24, 2011) A scientist investigating why ... coordination has found that key eye reflexes are substantially altered. ... researcher Alberto Costa, MD, Ph.D., could lead to new tools ... at improving quality of life for those with this genetic ...
... The delivery system for an important class of proteins ... mere three components, according to a new study. ... percent of the membrane proteins in a cell, are known ... membrane after construction. New research from the University of Chicago ...
Cached Biology News:Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 2Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 3Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 4Researcher finds altered cerebella in those with Down syndrome 2Three-part handoff delivers proteins to membrane surface 2Three-part handoff delivers proteins to membrane surface 3
Request Info...
... is formulated specifically for Alkaline Phosphatase conjugates. ... of activity for both the enzyme and ... dilution. This product has been chemically ... customer a longer shelf life, resistance to ...
... binding is a problem in your ... immobilized NeutrAvidin products as superior alternatives ... a modified avidin derivative that combines ... biotin-binding protein with exceptionally low nonspecific ...
... 4000 workstation is the simplest, easiest-to-use system ... automated liquid handling capabilities,into their labs, or ... support routine applications on a separate instrument. ... automation even when you have thousands ...
Biology Products: